Abstract
SMURF2 is a member of the HECT family of E3 ubiquitin ligases that have important roles as a negative regulator of transforming growth factor‐β (TGF‐β) signaling through ubiquitin‐mediated degradation of TGF‐β receptor I. However, the regulatory mechanism of SMURF2 is largely unknown. In this study, we identified that micro(mi)R‐195 and miR‐497 putatively target SMURF2 using several target prediction databases. Both miR‐195 and miR‐497 bind to the 3′‐UTR of the SMURF2 mRNA and inhibit SMURF2 expression. Furthermore, miR‐195 and miR‐497 regulate SMURF2‐dependent TβRI ubiquitination and cause the activation of the TGF‐β signaling pathway in lung cancer cells. Upregulation of miR‐195 and miR‐497 significantly reduced cell viability and colony formation through the activation of TGF‐β signaling. Interestingly, miR‐195 and miR‐497 also reduced the invasion ability of lung cancer cells when cells were treated with TGF‐β1. Subsequent in vivo studies in xenograft nude mice model revealed that miR‐195 and miR‐497 repress tumor growth. These findings demonstrate that miR‐195 and miR‐497 act as a tumor suppressor by suppressing ubiquitination‐mediated degradation of TGF‐β receptors through SMURF2, and suggest that miR‐195 and miR‐497 are potential therapeutic targets for lung cancer.
Highlights
Transforming growth factor-b (TGF-b) signaling acts as a key regulator of tissue homeostasis and carcinogenesis, according to growing clinical evidence
Previous studies have shown that this region is deleted in peritoneal carcinoma and breast cancer, and the expressions of miR-195 and miR-497 are downregulated in HCC, breast cancer and adrenocortical carcinoma (Flavin et al, 2009; Furuta et al, 2013; Koduru et al, 2017; Li et al, 2011)
We found that miR-195 and miR-497 expression levels were significantly downregulated in the tissue (Fig. 1A) and blood samples (Fig. 1B) of lung cancer patients
Summary
Transforming growth factor-b (TGF-b) signaling acts as a key regulator of tissue homeostasis and carcinogenesis, according to growing clinical evidence. Dysregulation of the TGF-b signaling pathway correlates with crucial roles in tumor initiation development and metastasis (Colak and Ten Dijke, 2017). The roles of the TGF-b signaling pathway depend on the different stages of cancer and on the differences between genetic backgrounds (Zarzynska, 2014). In early-stage cancer cells, this signaling pathway has tumor-suppressor functions including apoptosis and inhibition of cell proliferation. Its high activity in late-stage cancer tends to promote cell growth and to exhibit aggressive behavior.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.